Back | Next |
home / stock / scyx / scyx message board
Subject | By | Source | When |
---|---|---|---|
$SCYX Chart | conix | investorshub | 06/10/2021 6:03:03 PM |
Today is the day! Please no delay on | NoobyDoo | investorshub | 06/01/2021 1:07:47 PM |
A blessed Memorial Day for all that have | NoobyDoo | investorshub | 06/01/2021 12:24:13 AM |
SCYX - SCYNEXIS | Run22222 | investorshub | 05/26/2021 6:31:07 PM |
So exciting -> $IMO the After Hrs | GMA13 | investorshub | 01/01/2021 4:57:55 PM |
We are sitting on a potentially a gold | GMA13 | investorshub | 01/01/2021 4:33:54 PM |
Insiders started loading this one up on 12/21! | mr2d2 | investorshub | 12/23/2020 2:43:55 PM |
SCYNEXIS Announces FDA Acceptance and Priority Review of | Alyssa | investorshub | 12/07/2020 5:14:48 PM |
Average price target $31.25 - In the last | Alyssa | investorshub | 11/23/2020 8:17:21 PM |
It should pop of shortly. Picking up shares | Foontik1 | investorshub | 10/21/2020 1:22:46 PM |
Something is going on! I am in. GLTA | sabadollar | investorshub | 10/08/2020 5:39:11 PM |
I closed the books on this pile of | dabonenose | investorshub | 07/16/2020 10:34:31 PM |
$SCYX plans on holding an investor event on | GMA13 | investorshub | 07/13/2020 12:31:52 AM |
I received a thank you & was also | GMA13 | investorshub | 06/23/2020 1:09:41 AM |
$IMO but not to Advise: | GMA13 | investorshub | 06/23/2020 12:21:08 AM |
And your response was...... | dabonenose | investorshub | 05/17/2020 4:12:31 PM |
znewcar1: SCYX 7% v2M C1.15 f97M H1.19 twice as much float and 3/4 the price had some good vol last | znewcar1 | investorshangout | 02/20/2020 2:31:44 AM |
znewcar1: 25% v2,6M c1.58 f47,971,673 H1.61 nice bull flag. | znewcar1 | investorshangout | 03/14/2019 8:54:42 PM |
znewcar1: 41.67% v27,443,301 c1.020000 47,971,673 Open 1.3 and fell all day | znewcar1 | investorshangout | 01/31/2019 10:14:04 PM |
znewcar1: 2019-0107 25.26% 1,003,296 .768500 47,971,673 | znewcar1 | investorshangout | 01/19/2019 7:08:38 PM |
News, Short Squeeze, Breakout and More Instantly...
SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024 Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity ...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY C...